G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Ali Al Ameri,Elias Jabbour,Guillermo Garcia-Manero,Susan O'Brien,Stefan Faderl,Farhad Ravandi,Jianqin Shan,Sherry Pierce,Jorge E. Cortes,Hagop M. Kantarjian +9 more
TL;DR: Prognosis in MDS is directly associated with the severity of thrombocytopenia, and it was predicted for worse outcome within each of the International Prognostic Scoring System risk groups.
Journal ArticleDOI
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*
Amy E. DeZern,Amer M. Zeidan,John Barnard,Wesley Hand,Najla Al Ali,Francis Brown,Cassie Zimmerman,Gail J. Roboz,Guillermo Garcia-Manero,David P. Steensma,Rami S. Komrokji,Mikkael A. Sekeres +11 more
TL;DR: First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA) but Variables have not identified differential response rates between these, and the influence of patient sex on outcomes including overall survival is assessed.
Journal ArticleDOI
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Koji Sasaki,Hagop M. Kantarjian,Nicholas J. Short,Bachar Samra,Joseph D. Khoury,Rashmi Kanagal Shamanna,Marina Konopleva,Nitin Jain,Courtney D. DiNardo,Rita Khouri,Guillermo Garcia-Manero,Tapan M. Kadia,William G. Wierda,Issa F. Khouri,Partow Kebriaei,Rohtesh S. Mehta,Richard E. Champlin,Rebecca Garris,Cora M. Cheung,Naval Daver,Philip A. Thompson,Musa Yilmaz,Farhad Ravandi,Elias Jabbour +23 more
TL;DR: In this paper, a 3-month complete molecular response (CMR) is a major prognostic factor for survival in patients with PH-positive acute lymphoblastic leukemia (ALL).
Journal ArticleDOI
Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine
Hagop M. Kantarjian,Frank Giles,Peter L. Greenberg,Ronald Paquette,Eunice S. Wang,Janice Gabrilove,Guillermo Garcia-Manero,Julie Gray,Kuolung Hu,Janet Franklin +9 more
TL;DR: Romiplostim reduced pt incidence of clinically significant thrombocytopenic events and platelet txns, and improved platelet nadir in MDS pts receiving azacytidine in this study, consistent with increased platelet counts over time.
Journal ArticleDOI
Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
Alireza Eghtedar,Hagop M. Kantarjian,Elias Jabbour,Susan O'Brien,Elizabeth M. Burton,Guillermo Garcia-Manero,Srdan Verstovsek,Farhad Ravandi,Gautam Borthakur,Marina Konopleva,Alfonso Quintás-Cardama,Jorge E. Cortes +11 more
TL;DR: It is concluded that treatment failure after first-line therapy with 2G-TKIs is mostly associated with toxicity or patient preference, and these patients respond well to alternative TKIs.